A phase II clinical trial will be carried out with the objective of studying the impact of
the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome
(ARDS) in patients with severe or critical SARS-CoV-2 infection. Due to the high mortality of
severe forms of SARS-CoV-2 and for ethical reasons, a control arm will not be included.
Patients will be recruited by signing an informed consent and the baseline variables of
interest will be recorded. Tocilizumab will be administered in one or two doses, depending on
the case, and will be followed up for 30 days. The response to treatment, survival and
evolution will be studied. Factors associated with improvement of ARDS and survival will be
identified through multivariate analyzes. The results will be compared with those reported
internationally.